BRAF and thyroid gland follicular carcinoma: In 11 BRAF mutation-negative patients among 42 patients with ATA high and intermediate recurrence risk follicular thyroid cancers, the OCAv3 and ThyroSPEC analyses detected 2 NTRK fusions and 2 RET fusions (36%) (2 identified during pre-screening with ThyroSPEC and 2 identified during subsequent OCAv3 analysis).